Ovid Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Ovid Therapeutics

31/07/2024 14:41

* Ovid Therapeutics Inc  OVID.OQ   OVID.O  is expected
to show a
fall in quarterly revenue when it reports  results on August 2
(estimated) for the period ending June 30 2024
    * The New York City-based  company is expected to report a
6.7% decrease in revenue to $70 thousand from $75 thousand a
year ago, according to the mean estimate from 6 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Ovid Therapeutics Inc is
for a
loss of 22 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.2%
in the last three months. ​
    * Wall Street's median 12-month price target for Ovid
Therapeutics
Inc is $3.00​, above​ its last closing price of $1.05. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   0.25        -0.22                        22
 Dec. 31 0001  0.25        -0.05                        -342.6
 Jan. 1 0001   -0.19       -0.19      -0.16     Beat    15.2​
 Jun. 30 2023  -0.20       -0.20      -0.18     Beat    12
 ​​Jan.        -0.17       -0.17      -0.19     Missed  -10.9
 1 0001                                                 
 Dec. 31 2022  -0.17       -0.18      -0.16     Beat    12.2​
 Jan. 1 0001   -0.21       -0.21      -0.17     Beat    20.7
 Jun. 30 2022  -0.25       -0.25      -0.21     Beat    15.6
 This summary was machine generated July 31 at 13:41 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)